Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Open accessThe DOI matches its Crossref record; 41 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Glucagon-like peptide-1 receptor agonists have become established as a leading class of diabetes medications. However, these peptide-based drugs are administered by subcutaneous injection or, in one case, by a complex oral dosing regimen. We now report the discovery of LY3502970, a potent and selective small-molecule GLP-1R agonist. LY3502970 exhibits preclinical pharmacology equivalent to a marketed injectable GLP-1R agonist and possesses pharmacokinetic properties compatible with oral dosing in humans. Cryoelectron microscopy (cryo-EM) studies reveal an ECD-driven receptor binding mode for LY3502970 that provides a favorable pharmacological profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. Trp33ECD mediates key interaction with LY3502970 and the surrounding region. (A) Amino acid sequence comparison of the ECD regions for GLP-1Rs of different species. (B) LY3502970 increases cAMP accumulation in HEK293 cells expressing a chimeric form of the mouse GLP-1R (domains shown in green) where the N-terminal 142 residues have been replaced by the corresponding region of the human GLP-1R (domains shown in blue). (C) Mutation of Ser33ECD to Trp33ECD in the mouse GLP-1R enables LY3502970 to stimulate receptor-induced cAMP accumulation, while the reciprocal mutation (D) in the human GLP-1R abolishes compound function. The chimera and mutant data are presented as the mean ± SD of three independent experiments. (E) Trp33ECD interacts with LY3502970 and residues on TM2, ECL1, and ECL2. Residues and ligands are shown by sticks except Trp33ECD, which is also shown by spheres. Hydrogen bonds are indicated by dashed lines. (F) GLP-1R ECD orientation in the LY3502970 bound structure stabilized by aromatic interactions with ECL1. (G) The unique ECD orientation of ECD in the LY3502970 bound structure as a result of the unique Trp33ECD position. The structures of GLP-1R bound to LY3502970 (7TM in green, ECD in blue green, LY3502970 in magenta), GLP-1 (yellow, PDB ID code 6VCB), and peptide 5 (gray, PDB ID code 5NX2) are aligned. Trp33ECD is shown by a stick. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J) are not shown here, but their ECD orientations are very similar to GLP-1 bound structure 6VCB in yellow. (H and I) Competitive inhibition of [125I]GLP-1(7-36) binding to membranes isolated from cells expressing the human GLP-1R (H) or human W33S GLP-1R (I). Data are represented as the mean ± SD of three independent experiments.](https://figures.cochat.ai/paper-figures/acc41917547f432fb9ba49113ec198cd/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-2.jpg)


![Fig. 5. LY3502970 enhances glucose-stimulated insulin secretion and reduces food consumption in cynomolgus monkeys. (B–E) Effects of LY3502970 in IVGTT experiments. (A) Schematic diagram of the IVGTT procedure in anesthetized cynomolgus monkeys. Dosing of LY3502970 or exenatide was performed by manual bolus injection, followed by continuous infusion for 80 min. Forty minutes after initiating dosing of vehicle or the drug, glucose was administered intravenously. (B and C) Effect of LY3502970 (B) or exenatide (C) on blood glucose levels. (D and E) Effect of LY3502970 (D) or exenatide (E) on serum insulin levels. Data are represented as the mean ± SEM (n = 7). Significantly different from vehicle 1 or vehicle 2 by Dunnett’s test at *P < 0.025 and **P < 0.005 (one tailed), respectively. Vehicle 1: PEG400/PG/Gly NaOH buffer (pH 9), vehicle 2: 0.05% Tween80 PBS. (F and G) Mean food consumption following administration of LY3502970 (F) or exenatide (G). Cynomolgus monkeys were administered LY3502970, exenatide, or vehicle once daily for 5 d with a 2 d recovery period using an 8 × 5 cross-over design. Food consumption during the 90 min period after feeding was measured. Data are represented as the mean ± SEM (n = 8). Significantly different from the vehicle group by Dunnett’s test at **P < 0.005 (one tailed). Vehicle: dimethyl sulfoxide (DMSO)/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + 0.05% Tween80 PBS [s.c.], LY3502970: LY3502970 [p.o.] + 0.05% Tween 80 PBS [s.c.], exenatide: DMSO/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + exenatide [s.c.].](https://figures.cochat.ai/paper-figures/a9b9ab625235418ca4ecc2d8317f67c4/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More specifically, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β-arrestin recruitment at the GLP-1 receptor [23].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, orforglipron demonstrated a terminal half-life of 29-49 h in a phase 1b study in people with T2D, which allows once-daily oral dosing [25,28].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous report, treatment with orforglipron was found to promote glucose-dependent insulin secretion after a glucose challenge [25].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orforglipron is an orally administered, non-peptide GLP-1 receptor agonist that can be taken once daily. However, it binds differently to the GLP-1 receptor compared to native GLP-1, thereby inducing G-protein activation rather than beta-arrestin recruitment [107].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [107]
Experimental — accuracy not yet measuredIn the citing paper
“As a small molecule, orforglipron is chemically stable in the acidic gastric environment and is not a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33,34,35”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 1×
“This starting model was then subjected to iterative rounds of manual and Real Space Refinement in Coot (47, 48) and Phenix (49), respectively.”
MethodGuide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777 · cited 2×
“S. Q. Zheng et al., MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy.”
MethodPHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621 · cited 1×
“Bayesian polishing and CTF refinement (46) were applied to further improve the map, resulting in a 3.”
MethodMolProbity: More and better reference data for improved all‐atom structure validation
Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., et al. (2018) · Protein Science · doi:10.1002/pro.3330 · Cited by 4,599 · cited 1×
“The final model was visually inspected for general fit to the map, and geometry was further evaluated using Molprobity (50).”
MethodGctf: Real-time CTF determination and correction
Zhang, K. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.11.003 · Cited by 3,537
Guide for the Care and Use of Laboratory Animals: Eighth Edition -- Tamil Version
Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Studies, D. O. E. A. L., & National Research Council (2011) · National Academies Press eBooks · doi:10.17226/25801 · Cited by 1,118
Research works printed but not linked: 1
- T. Nguyen, Drug structures displayed for the first time in Orlando. Chem. Eng. News (2019).
Cited by
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“More speci fi cally, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β -arrestin recruitment at the GLP-1 receptor [23].”
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“LY3502970 (now known as orforglipron) is a small-molecule GLP-1RA, originally discovered by Chugai Pharmaceuticals, that acts as a partial agonist at the GLP-1R, biased towards G protein activation relative to negligible recruitment of β-arrestin 57 .”
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Singh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
“For instance, the commercial production of the current long-chain GLP-1RAs is not cost-effective, whereas DPP-4is are more expensive than sulfonylureas.”
InfluentialCampbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Structural determinants of dual incretin receptor agonism by tirzepatide
Sun, B., Willard, F. S., Feng, D., Alsina‐Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116506119 · Cited by 136
“, The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.”
BackgroundMethodInfluentialSelf-citationOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Current Advances in the Management of Diabetes Mellitus
Aloke, C., Egwu, C. O., Aja, P. M., Obasi, N. A., Chukwu, J. A., Akumadu, B. O., Ogbu, P. N., & Achilonu, I. (2022) · Biomedicines · doi:10.3390/biomedicines10102436 · Cited by 157
“The molecule is highly potent and selective against other class B G-protein-coupled receptors (GPCRs) with a pharmacokinetic profile favorable for oral administration [66].”
BackgroundThe therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 107
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor
Cong, Z., Chen, L.-N., Ma, H., Zhou, Q., Zou, X., Ye, C., Dai, A., Liu, Q., Huang, W., Sun, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24058-z · Cited by 89
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“Non‐peptide small GLP‐1 receptor agonists Recently, novel insights into the binding characteristics of the GLP-1 receptor have allowed the development of non-peptide GLP-1 receptor activators [41, 42].”
BackgroundStructural perspective of class B1 GPCR signaling
Cong, Z., Liang, Y.-L., Zhou, Q., Darbalaei, S., Zhao, F., Feng, W., Zhao, L., Xu, H. E., Yang, D., & Wang, M.-W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.01.002 · Cited by 80
Piper, S. J., Johnson, R. M., Wootten, D. L., & Sexton, P. M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00837 · Cited by 81
Karakasis, P., Patoulias, D., Pamporis, K., Stachteas, P., Bougioukas, K. I., Klisic, A. N., Fragakis, N., & Rizzo, M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155710 · Cited by 77
New Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S. J., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 77
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Ansari, M. A., Chauhan, W., Shoaib, S., Alyahya, S. A., Ali, M., Ashraf, H., Alomary, M. N., & Al-Suhaimi, E. A. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01369-3 · Cited by 73
“In the precursor protein, these peptide sequences are typically inactive; they become active during food processing or enzymatic hydrolysis [139].”
BackgroundPratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15184 · Cited by 62
“Orforglipron is among the first of a new generation of chemically synthesized, non-peptide GLP-1RAs that feature oral bioavailability without the need of co-formulations containing complex absorption enhancing agents.(4,5) In preclinical studies, cryogenic electron microscopy has shown that orforglipron binds within t…”
BackgroundResultInfluentialSelf-citationConserved class B GPCR activation by a biased intracellular agonist
Zhao, L., He, Q., Yuan, Q., Gu, Y., He, X., Shan, H., Li, J., Wang, K., Li, Y., Hu, W., et al. (2023) · Nature · doi:10.1038/s41586-023-06467-w · Cited by 64
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60
“The most common adverse events were gastrointestinal-related, and occurred early in treatment, similar to find- ings with other GLP-1RAs.”
BackgroundInfluentialSelf-citationThe pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp5765 · Cited by 52
Self-citationDrugFlow: An AI-Driven One-Stop Platform for Innovative Drug Discovery
Shen, C., Song, J., Hsieh, C., Cao, D., Kang, Y., Ye, W., Wu, Z., Wang, J., Zhang, O., Zhang, X., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00621 · Cited by 61
Eid, L. E., Reynolds, C. A., Tomás, A., & Jones, B. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106411 · Cited by 57
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 42
“Of those, tryptophan at position 33 in the ECD (Trp33ECD) confers species selectivity; subsequent preclinical studies have thus screened agonists with primates with Trp33ECD or receptor mutants with substitution of Ser33ECD by Trp33ECD.”
BackgroundInfluentialStructural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“However, it binds differently to the GLP-1 receptor compared to native GLP-1, thereby inducing G-protein activation rather than beta-arrestin recruitment [107].”
BackgroundCong, Z., Zhou, Q., Li, Y., Chen, L.-N., Zhang, Z.-C., Liang, A., Liu, Q., Wu, X., Dai, A., Xia, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200155119 · Cited by 41
“, GLP-1[9-36]NH2, lowers both the affinity and the efficacy of GLP-1 (23).”
BackgroundGLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“derivative and is a biased agonist that abolished β-arrestin signaling [103,112].”
BackgroundLi, Z., Chen, X., Vong, J. S. L., Zhao, L., Huang, J., Yan, L. Y. C., Ip, B., Wing, Y. K., Lai, H.-M., Mok, V. C. T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02208-9 · Cited by 42
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
Applications of Cryo-EM in small molecule and biologics drug design
Lees, J. A., Dias, J. M., & Han, S. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210444 · Cited by 43
Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
Laeremans, T., Sands, Z. A., Claes, P., Blieck, A. D., Cesco, S. D., Triest, S., Busch, A., Felix, D., Kumar, A., Jaakola, V., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.863099 · Cited by 48
“This strategy helped to obtain the first structure of GLP1R with a small molecule partial agonist, LY3502970, which is biased toward G protein over β-arrestin (Kawai et al., 2020).”
BackgroundMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“…is a potent non-peptide partial agonist of the GLP-1 receptor that has a greater effect on cyclic AMP (cAMP) signaling than on β-arrestin recruitment (i.e. it is a biased agonist) – a pharmacologic profile that may offer lower receptor desensitization than full GLP-1 receptor agonists [60].”
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism
Duan, J., He, X., Li, S., & Xu, H. E. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00957-1 · Cited by 47
“For example, orforglipron (LY3502970) (an orally active non-peptide partial agonist for GLP1R) exhibits the ability to activate the receptor G protein pathway to the same maximum levels as full agonists, while it shows deficiencies in promoting receptor β-arrestin recruitment 22 .”
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01554-1 · Cited by 38
“In a previous report, treat-ment with orforglipron was found to promote glucose-dependent insulin secretion after a glucose challenge [25].”
BackgroundSelf-citationRosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W.-S., Liu, R., Zhao, Y., Manghi, F. P., Abalos, F., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00202-3 · Cited by 49
van der Velden, W. J. C., Smit, F. X., Christiansen, C. B., Møller, T. C., Hjortø, G. M., Larsen, O., Schiellerup, S. P., Bräuner‐Osborne, H., Holst, J. J., Hartmann, B., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00193 · Cited by 42
Dutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism
Lees, J. A., Dias, J. M., Rajamohan, F., Fortin, J., O’Connor, R., Kong, J., Hughes, E. A. G., Fisher, E. L., Tuttle, J. B., Lovett, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41646-3 · Cited by 42
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
“…under investigation and will be Orforglipron is an orally available nonpeptide GLP-1 receptor partial agonist, which demonstrates a greater effect on cyclic AMP signaling than b - arrestin recruitment, leading to lower receptor desensitization than that of full GLP-1 receptor agonist [49].”
BackgroundBiased signaling in GPCRs: Structural insights and implications for drug development
Ma, Y., Patterson, B., & Zhu, L. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108786 · Cited by 36
The rapidly evolving role of cryo-EM in drug design
Wigge, C., Stefanovic, A., & Radjainia, M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.12.003 · Cited by 35
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“Orforglipron, an oral, non-peptide, G-protein biased GLP-1 RA (resulting in lower activation of the beta-arrestin pathway) is currently under development for the treatment of T2D and obesity [29].”
BackgroundCryo-electron microscopy-based drug design
Cebi, E., Lee, J., Subramani, V. K., Bak, N., Oh, C., & Kim, K. K. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1342179 · Cited by 38
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Binding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 34
A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
Douros, J. D., Novikoff, A., DUBOIS, B. N., Rohlfs, R., Mokrosiński, J., Hogendorf, W. F. J., Augustin, R., Merkestein, M., Martini, L. B. E., Linderoth, L., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102124 · Cited by 25
“Additionally, numerous small molecule GLP-1R agonists including orforglipron (LY3502970) [27] are heavily cAMP-biased, partial agonists.”
The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 31
Willard, F. S., Wainscott, D. B., Showalter, A. D., Stutsman, C., Ma, W., Cardona, G. R., Zink, R. W., Corkins, C. M., Chen, Q., Yumibe, N. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00029 · Cited by 23
Self-citationChen, L., Yun, Y., Guo, S., Wang, X., Xiong, M., Zhao, T., Xu, T., Shen, J., Xie, X., & Wang, K. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00320 · Cited by 24
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“While structural studies have provided important insights into binding topology and receptor conformational changes [30,32,33,36–39], the extent to which different allosteric ligands induce biased signaling or differential receptor trafficking is not fully resolved.”
InfluentialAllosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site
Wang, J., Yang, D., Cheng, X., Yang, L., Wang, Z., Dai, A., Cai, X., Zhang, C., Yuliantie, E., Liu, Q., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00552 · Cited by 24
Yuan, S., Xia, L., Wang, C., Wu, F., Zhang, B., Pan, C., Fan, Z., Lei, X., Stevens, R. C., Šali, A., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00063 · Cited by 21
Liao, H.-J., & Tzen, J. T. C. (2022) · Metabolites · doi:10.3390/metabo12060549 · Cited by 21
“The labeling of these important amino acids is based on the related studies of GLP-1 agonists [7,21].”
BackgroundInfluentialLiu, N., Cui, X. Y., Yan, W., Guo, T., Wang, Z., Wei, X., Sun, Y., Liu, J., Cheng, X., Ma, W., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100968 · Cited by 26
“The further re-searches revealed that non-peptide ligands, for example 4-(3-(Benzyloxy)phenyl)-2-(ethylsul fi nyl)-6-(tri fl uoromethyl)pyrimidine (BETP) [19], compound 2 and B [20] and LY3502970 [17] can activate GLP-1R and perform the similar effects like GLP-1 analogues.”
BackgroundLiu, N., Cui, X., Guo, T., Wei, X., Sun, Y., Liu, J., Zhang, Y., Ma, W., Yan, W., & Chen, L. (2024) · Antioxidants · doi:10.3390/antiox13101246 · Cited by 31
“The discovery of LY3502970 [52], RGT1383 [55], compound 2 [56], and TT15 [57] has highlighted the potency of these compounds in GLP-1R activation.”
Haggag, A. Z., Xu, J., Butcher, L., Pagnussat, S., Davies, G., Lundqvist, S., Wang, W., van Zuydam, N. R., Nelander, K., Jha, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16047 · Cited by 22
“24,29 Indeed, human-equivalent doses that potentiated maximal insulin secretion in NHPs, that is, 10 and 30 mg, were administered to humans without up-titration and were associated with acceptable tolerability.”
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
“57,58 This may explain its pronounced glucose-lowering and weight-reduction effects.”
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
“48 In a phase 2, randomized trial of obese patients who received one of four doses of orforglipron or placebo, 46%-75% of the participants on the active drug had a weight loss of up to 10% at 36 weeks, compared to 9% of those on placebo.”
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Buckeridge, C., Tsamandouras, N., Carvajal‐Gonzalez, S., Brown, L. S., Hernandez‐Illas, M., & Saxena, A. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15643 · Cited by 20
Behera, L. M., Ghosh, M., & Rana, S. (2022) · Amino Acids · doi:10.1007/s00726-022-03175-z · Cited by 18
“1 3 clinical trials is very encouraging (Cong et al. 2022; Kawai et al. 2020), which suggests that conformationally ordered shorter peptide agonists with better pharmacokinetic properties can be designed for targeting the GLP-1R (Fig.”
BackgroundLymperopoulos, A., Altsman, V. L., & Stoicovy, R. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157239 · Cited by 27
“…against obesity, all of which invariably prove to be G s /cAMP-“biased” agonists upon pharmacological characterization (which is also perhaps why they have enhanced weight loss efficacy) [9,53,66,67], turn out to be G s /cAMP-“biased” exactly because native GLP-1R is inherently G s /cAMP-“biased”.”
Ye, X., Liu, S., Liu, Y., Qian, Z., Liu, H., Zhang, B., Guo, T., Thompson, G. J., Stevens, R. C., Sharpless, K. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220767120 · Cited by 16
“2220767120 3 of 11 presence of the endogenous peptide GLP-1(9-36).”
BackgroundMethodInfluentialGiri, A., Mehan, S., Khan, Z., Gupta, G. D., & Narula, A. S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115831 · Cited by 18
Nauck, M. A., & Horowitz, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01201-1 · Cited by 16
Therapeutic peptides and proteins: Status and developments in drug delivery
Hornsby, B. D., Lee, C. H., Steele, C. A., Tuekpe, J. K. K., & Lim, C. S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114895 · Cited by 24
Xie, Y., Zhou, Q., He, Q., Wang, X., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.008 · Cited by 17
Odoemelam, C. S., Hunter, E., Simms, J., Ahmad, Z., Chang, M., Percival, B. C., Williams, I. H., Molinari, M., Kamerlin, S. C. L., & Wilson, P. (2022) · Applied Biosciences · doi:10.3390/applbiosci1020010 · Cited by 21
“1 Å) [23]) have been crystallised using methods such as electron microscopy and x-ray diffraction.”
MethodTilinca, M. C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.1.1 · Cited by 20
Kage, M., Hayashi, R., Matsuo, A., Tamiya, M., Kuramoto, S., Ohara, K., Irie, M., Chiyoda, A., Takano, K., Ito, T., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117830 · Cited by 16
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
Daley, E. J., Yoon, S.-H., Reyes, M., Bruce, M., Brooks, D. J., Bouxsein, M., Potts, J. T. J., Kronenberg, H. M., Wein, M. N., Lanske, B., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac054 · Cited by 14
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs
Ueda, K., Porter, C. J. H., Goodwin, A. K., & Taylor, L. S. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01407-5 · Cited by 21
“However, orforglipron challenged this notion and has a unique interaction with the GLP-1 receptor that is distinct from peptide counterparts 25 .”
Cardiovascular effects of GLP-1 receptor agonism
Winquist, R. J., & Gribkoff, V. K. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.02.005 · Cited by 16
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
“Orforglipron, a biased partial agonist of the GLP-1R with lower activation of the b -arrestin pathway (28), resulted in body weight reductions up to 12.6% (placebo adjusted) at 36 weeks in obese non-diabetic patients (29) while Danuglipron, a GLP-1R full agonist achieved approximately up to 4-5%…”
BackgroundInfluentialPatil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 12
Advances in small-molecule insulin secretagogues for diabetes treatment
Su, J., Xu, J., Hu, S., Ye, H., Xie, L. N., & Ouyang, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117179 · Cited by 20
DiffMC‐Gen: A Dual Denoising Diffusion Model for Multi‐Conditional Molecular Generation
Yang, Y., Gu, S., Liu, B., Gong, X., Lu, R., Qiu, J., Yao, X., & Liu, H. (2025) · Advanced Science · doi:10.1002/advs.202417726 · Cited by 20
Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery
Mizera, M., & Latek, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084060 · Cited by 15
“Namely, three additional small-molecule binding sites of GLP-1R, located in or close to the TMD orthosteric site, have been revealed, providing a complete picture of class B GPCRs activation [13,14,16,17].”
BackgroundBoianelli, A., Nordell, P., Earl, J., Naylor, J., Hornigold, D. C., Jansson‐Löfmark, R., & Sundqvist, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101310 · Cited by 15
“Semaglutide is the only GLP-1RA currently available both in a subcutaneous and an oral formulation, with the oral tablet being approved in 2019 [16], but currently, there are several GLP-1RAs in the clinical phase aiming for oral delivery [17,18].”
BackgroundGomaa, M. S., Alturki, M. S., Tawfeeq, N., Hussein, D. A., Pottoo, F. H., Khzem, A. H. A., Sarafroz, M., & Abubshait, S. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121607 · Cited by 14
Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics
Gangwal, A., & Lavecchia, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104333 · Cited by 17
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“scaffolds that could be chemically optimized with the aim of improving pharmacological and pharmacokinetic properties 236,238 .”
Liu, L., Rashid, M., & Wess, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00867 · Cited by 16
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“[178].”
InfluentialWang, X., Yun, Y., Chen, L., Guo, S., Niu, B., Fang, J., Yuan, Q., Shen, J., Xie, X., & Wang, K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117761 · Cited by 12
Diabetology and Nanotechnology: A Compelling Combination
Karwasra, R., Sharma, S., Sharma, I., Shahid, N., & Umar, T. (2023) · Recent Patents on Nanotechnology · doi:10.2174/0118722105253055231016155618 · Cited by 12
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Chen, X., Xu, S., Yang, S. C., Yu, Z.-Z., Chen, Y., Wu, H., Bao, Q., You, Q., Guo, X., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02616 · Cited by 11
Biased agonism in peptide-GPCRs: A structural perspective
Jayakody, T., Budagoda, D. K., Mendis, K., Dilshan, W. D., Bethmage, D., Dissasekara, R., & Dawe, G. S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108806 · Cited by 11
Dong, G., Ye, Q., Li, W., Zhang, S., Yang, Z., Zhang, R., Ta, D., Li, H., Zhang, Y., Zhang, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00242 · Cited by 10
Metadata
- Authors
- Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W.
- Affiliations
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- ConfometRx (United States) (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Suzuki, Yoshiyuki
- Kobilka, Brian K.
- Sloop, Kyle W.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-11-11
- Volume
- 117
- Issue
- 47
- Pages
- 29959-29967
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7703558
- OpenAlex
- W3099724881
- Cited by
- 231
- References
- 51
- Citations by year
- 2026: 68 · 2025: 53 · 2024: 44 · 2023: 30 · 2022: 19 · 2021: 15 · 2020: 2
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, class B G protein-coupled receptors, receptor structure, partial agonism, biased signaling, G protein activation, beta-arrestin, oral antidiabetic drugs, type 2 diabetes, insulin secretion, blood glucose reduction, non-human primates
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Aminopyridines, Animals, Benzamides, Humans, Hypoglycemic Agents, Macaca fascicularis, Male, Mice, Transgenic, Models, Molecular, Species Specificity, Swine, Tryptophan, Mutagenesis, Site-Directed, Anti-Obesity Agents, Cryoelectron Microscopy, Mice, Rats, Incretins, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.